Protagonist Therapeutics Inc [PTGX] stock is trading at $38.50, up 2.42%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PTGX shares have gain 6.94% over the last week, with a monthly amount drifted -1.58%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on December 06, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $47. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $62. On November 05, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $58 on the stock. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $65 on September 24, 2024. Truist initiated its recommendation with a Buy and recommended $60 as its price target on September 09, 2024. CapitalOne started tracking with a Overweight rating for this stock on October 30, 2023, and assigned it a price target of $32.
Protagonist Therapeutics Inc [PTGX] stock has fluctuated between $24.22 and $48.89 over the past year. Currently, Wall Street analysts expect the stock to reach $57.33 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $38.50 at the most recent close of the market. An investor can expect a potential return of 48.91% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Protagonist Therapeutics Inc [NASDAQ:PTGX] reported sales of 434.43M for the trailing twelve months, which represents a growth of 184.40%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.58%, Pretax Profit Margin comes in at 0.64%, and Net Profit Margin reading is 0.63%. To continue investigating profitability, this company’s Return on Assets is posted at 0.37, Equity is 0.48 and Total Capital is 0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.30 points at the first support level, and at 34.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.61, and for the 2nd resistance point, it is at 44.71.
Ratios To Look Out For
For context, Protagonist Therapeutics Inc’s Current Ratio is 12.48. As well, the Quick Ratio is 12.48, while the Cash Ratio is 2.05. Considering the valuation of this stock, the price to sales ratio is 5.44, the price to book ratio is 3.48 and price to earnings (TTM) ratio is 9.15.
Transactions by insiders
Recent insider trading involved PATEL DINESH V PH D, President and CEO, that happened on Feb 19 ’25 when 5359.0 shares were sold. Chief Medical Officer, MOLINA ARTURO MD completed a deal on Nov 27 ’24 to sell 26000.0 shares. Meanwhile, Chief Medical Officer MOLINA ARTURO MD sold 5529.0 shares on Nov 26 ’24.
